Analyst Price Targets — CLDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 9:29 am | — | Barclays | $53.00 | $41.56 | TheFly | Celldex price target raised to $53 from $48 at Barclays |
| July 29, 2026 10:08 am | — | Wells Fargo | $72.00 | $35.58 | TheFly | Celldex price target raised to $72 from $48 at Wells Fargo |
| July 22, 2026 11:34 am | — | Cantor Fitzgerald | $61.00 | $35.66 | TheFly | Celldex price target lowered to $61 from $67 at Cantor Fitzgerald |
| July 22, 2026 11:05 am | — | Wells Fargo | $48.00 | $35.66 | TheFly | Celldex price target lowered to $48 from $54 at Wells Fargo |
| July 22, 2026 10:49 am | — | Morgan Stanley | $40.00 | $35.66 | TheFly | Celldex price target lowered to $40 from $44 at Morgan Stanley |
| July 22, 2026 10:40 am | — | Canaccord Genuity | $60.00 | $35.66 | TheFly | Celldex price target lowered to $60 from $62 at Canaccord |
| July 22, 2026 10:04 am | — | Leerink Partners | $70.00 | $35.66 | TheFly | Celldex price target lowered to $70 from $78 at Leerink |
| July 20, 2026 11:07 am | Yatin Suneja | Guggenheim | $100.00 | $35.35 | TheFly | Celldex price target raised to $100 from $90 at Guggenheim |
| June 10, 2026 12:08 pm | — | UBS | $45.00 | $30.21 | TheFly | Celldex price target raised to $45 from $38 at UBS |
| May 13, 2026 10:48 am | Derek Archila | Wells Fargo | $54.00 | $32.00 | TheFly | Celldex price target raised to $54 from $38 at Wells Fargo |
Latest News for CLDX
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
California State Teachers Retirement System raised its holdings in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 36.4% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 79,630 shares of the biopharmaceutical company's stock after buying an additional 21,233 shares during the quarter. California State
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
Celldex Therapeutics (NASDAQ: CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies. Anthony Marucci, Celldex's co-founder, president and chief executive officer, said the company was
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLDX.
U.S. House Trading
No House trades found for CLDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.